Marksans Pharma Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Marksans Pharma verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 22.4%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 17%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 15.7%. Die Eigenkapitalrendite von Marksans Pharma beträgt 15.1% und die Nettomargen betragen 14.4%.
Wichtige Informationen
22.4%
Wachstumsrate der Gewinne
20.9%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 17.5% |
| Wachstumsrate der Einnahmen | 15.7% |
| Eigenkapitalrendite | 15.1% |
| Netto-Marge | 14.4% |
| Letzte Ertragsaktualisierung | 31 Mar 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Aufschlüsselung der Einnahmen und Ausgaben
Wie Marksans Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 24 | 21,774 | 3,137 | 2,936 | 0 |
| 31 Dec 23 | 21,034 | 3,164 | 2,875 | 0 |
| 30 Sep 23 | 19,971 | 2,965 | 2,752 | 0 |
| 30 Jun 23 | 19,184 | 2,743 | 2,637 | 0 |
| 31 Mar 23 | 18,521 | 2,653 | 2,521 | 0 |
| 31 Dec 22 | 17,842 | 2,123 | 2,436 | 0 |
| 30 Sep 22 | 16,670 | 2,004 | 2,375 | 0 |
| 30 Jun 22 | 15,756 | 1,847 | 2,326 | 0 |
| 31 Mar 22 | 14,908 | 1,868 | 2,250 | 0 |
| 31 Dec 21 | 14,069 | 2,367 | 2,351 | 0 |
| 30 Sep 21 | 14,026 | 2,473 | 2,269 | 0 |
| 30 Jun 21 | 14,064 | 2,518 | 2,037 | 0 |
| 31 Mar 21 | 13,762 | 2,385 | 2,096 | 0 |
| 31 Dec 20 | 13,817 | 2,018 | 1,908 | 0 |
| 30 Sep 20 | 13,142 | 1,724 | 1,833 | 0 |
| 30 Jun 20 | 12,203 | 1,476 | 1,700 | 0 |
| 31 Mar 20 | 11,344 | 1,208 | 1,785 | 0 |
| 31 Dec 19 | 10,463 | 879 | 1,719 | 0 |
| 30 Sep 19 | 9,972 | 834 | 1,677 | 0 |
| 30 Jun 19 | 10,099 | 780 | 1,631 | 0 |
| 31 Mar 19 | 10,001 | 804 | 1,659 | 0 |
| 31 Dec 18 | 9,523 | 666 | 1,601 | 0 |
| 30 Sep 18 | 9,223 | 582 | 1,599 | 0 |
| 30 Jun 18 | 9,272 | 463 | 1,474 | 0 |
| 31 Mar 18 | 9,127 | 358 | 1,534 | 0 |
| 31 Dec 17 | 8,918 | 343 | 1,528 | 0 |
| 30 Sep 17 | 8,949 | 275 | 1,550 | 0 |
| 30 Jun 17 | 8,015 | 187 | 1,492 | 0 |
| 31 Mar 17 | 7,672 | 113 | 1,547 | 0 |
| 31 Dec 16 | 7,926 | 70 | 1,475 | 0 |
| 30 Sep 16 | 7,948 | 136 | 1,458 | 0 |
| 30 Jun 16 | 8,699 | 481 | 1,424 | 0 |
| 31 Mar 16 | 8,933 | 785 | 1,270 | 0 |
| 31 Dec 15 | 8,536 | 1,093 | 1,585 | 0 |
| 30 Sep 15 | 8,495 | 1,191 | 1,397 | 0 |
| 30 Jun 15 | 8,045 | 1,154 | 728 | 0 |
| 31 Mar 15 | 7,967 | 1,094 | 758 | 0 |
| 31 Dec 14 | 7,850 | 950 | 1,482 | 0 |
| 30 Sep 14 | 7,405 | 897 | 1,121 | 0 |
| 30 Jun 14 | 6,914 | 786 | 693 | 0 |
| 31 Mar 14 | 6,300 | 719 | 1,091 | 0 |
| 31 Dec 13 | 5,950 | 1,020 | 1,013 | 0 |
| 30 Sep 13 | 5,406 | 877 | 994 | 0 |
| 30 Jun 13 | 4,848 | 817 | 588 | 0 |
Qualität der Erträge: MARKSANS einen hohen Anteil an unbarem Gewinn hat.
Wachsende Gewinnspanne: MARKSANSDie aktuellen Gewinnspannen (14.4%) sind höher als im letzten Jahr (14.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: MARKSANSIn den letzten 5 Jahren sind die Einnahmen von 24% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: MARKSANSDas Gewinnwachstum des Unternehmens im letzten Jahr (18.2%) liegt unter seinem 5-Jahres-Durchschnitt (22.4% pro Jahr).
Erträge im Vergleich zur Industrie: MARKSANS Das Gewinnwachstum im vergangenen Jahr (18.2%) übertraf nicht die Entwicklung der Branche Pharmaceuticals 18.2% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: MARKSANSDie Eigenkapitalrendite des Unternehmens (15.1%) wird als niedrig angesehen.